Paclitaxel-carboplatin-gemcitabine (TCG) Versus Paclitaxel-Carboplatin (TC) As First Line Treatment in Women with Ovarian Cancer: A Randomized Phase III GCIG Intergroup Study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102)

AK Stähle, C Jackisch,B Schmalfeldt, S Loibl,K Wollschläger,HJ Lück,U Canzler,A duBois

Thieme-Praxis-Report Geburtshilfe und Frauenheilkunde/Geburtshilfe und Frauenheilkunde（2006）

引用 0|浏览7

暂无评分

摘要

Aims: Ovarian cancer is still not curable in the majority of patients. Addition of non cross-resistant drugs to standard TC is a potential option for improvement of efficacy. G showed good activity in recurrent ovarian cancer. In phase II trials G cood be added to TC with manegeable toxicity. Therefore, a prospectively randomized phase III Intergroup study comparing TCG to standard TC was initiated within the GCIG network.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要